Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
Abstract Aims Large‐scale clinical trials have demonstrated clinical benefits of sacubitril–valsartan in symptomatic heart failure with reduced ejection fraction patients (PARADIGM‐HF), with potential benefits in patients hospitalized for acute decompensated heart failure (ADHF) (PIONEER‐HF) and few...
Saved in:
Main Authors: | David Carballo, Jérôme Stirnemann, Nicolas Garin, Chistophe Marti, Jacques Serratrice, Sebastian Carballo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-06-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.12676 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
by: Marcely Gimenes Bonatto, et al.
Published: (2020-06-01) -
Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits
by: Yu Chun, et al.
Published: (2021-09-01) -
Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy
by: Neeraj Hiremath, et al.
Published: (2024-04-01) -
Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
by: Charlotte Nordberg Backelin, et al.
Published: (2020-06-01) -
Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
by: Seonhwa Lee, et al.
Published: (2020-06-01)